Reviewing PrEP’s Effect on STI Incidence Among Men Who Have sex with Men—Balancing Increased STI Screening and Potential Behavioral Sexual Risk Compensation

Kumar, Sateesh; Haderxhanaj, Laura T.; Spicknall, Ian H.

doi:10.1007/s10461-020-03110-x

Cited by 23 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 However, an other study with 183 MSM in Seattle showed a decreased prevalence in condom use and a higher prevalence of STIs during PrEP use compared before PrEP initiation. 49…”

Section: Discussionmentioning

confidence: 99%

Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis

et al. 2021

View full text Add to dashboard Cite

Pre-exposure prophylaxis (PrEP) prevents HIV infection among men who have sex with men (MSM) and transgender women (TGW) who are the groups that presents the high incidence risk in Brazil. This cross-sectional secondary analysis describes possible risk compensation, attitudes, and beliefs regarding the use of PrEP among 723 MSM and TGW evaluated in the PrEP Brazil study pre-screening phase. Possible risk compensation was reported by 31.6% individuals. In the multivariate model, factors that increased the likelihood of possible risk compensation were: self-referring as white vs. Black (AOR 2.05; CI 1.09, 3.85), perceiving high likelihood of getting HIV in next 12 months (AOR 1.78; CI 1.23, 2.56), being less afraid of HIV infection if using PrEP (AOR 1.93; CI 1.19, 3.14), feeling liberated to have more partners if using PrEP (AOR 2.93; CI 1.92, 4.49), and believing closest friends would use PrEP (AOR 2.51; CI 1.1, 5.71). We found that possible risk compensation was more common among individuals who presented high-risk perception for HIV infection, probably reflecting they feel at risk and could benefit from PrEP use.

show abstract

“…44 However, an other study with 183 MSM in Seattle showed a decreased prevalence in condom use and a higher prevalence of STIs during PrEP use compared before PrEP initiation. 49…”

Section: Discussionmentioning

confidence: 99%

Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recent data show an increasing incidence of STIs amongst both non-PrEP and PrEP users, with the latter having a higher incidence of bacterial STIs and viral hepatitis C. is relationship is important to communicate with patients. PrEP, albeit effective against HIV, does not protect against any other STIs [86][87][88][89][90]. Baseline screening for STIs upon PrEP initiation should be repeated every three to six months in PrEP users, and HIV screening should be done every three months and upon diagnosis of an STI [23,70].…”

Section: Stis and Prepmentioning

confidence: 99%

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada

Knox

Pilarski

Dhunna

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

According to the Public Health Agency of Canada, approximately 62,050 people were living with HIV in Canada in 2018, and of those, 13% were undiagnosed. Currently, no single strategy provides complete protection or is universally effective across all demographic groups at risk for HIV. However, HIV preexposure prophylaxis (PrEP) is the newest HIV prevention strategy that shows promise. To date, two products have received an indication for PrEP by Health Canada: emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) and emtricitabine/tenofovir alafenamide (Descovy®; FTC/TAF). Despite the high efficacy of these PrEP intervention methods, access to PrEP in Canada remains low. Identifying and addressing barriers to PrEP access, especially in high-risk groups, are necessary to reduce HIV transmission in Canada. While guidelines published by the Center for Disease Control and Prevention (CDC) include FTC/TAF information, the efficacy of FTC/TAF for PrEP has not yet been considered in Canada’s clinical practice guidelines. Thus, the current paper reviews data regarding the use of FTC/TDF and FTC/TAF for PrEP, which may be useful for Canadian healthcare providers when counseling and implementing HIV prevention methods. The authors highlight these data in relation to various at-risk populations and review ongoing clinical trials investigating novel PrEP agents. Overall, FTC/TDF PrEP is effective for many populations, including men who have sex with men, transgender women, heterosexuals with partners living with HIV, and people who use drugs. While there is fewer data reported on the efficacy of FTC/TAF to date, recent clinical trials have demonstrated noninferiority of FTC/TAF in comparison to FTC/TDF. Notably, as studies have shown that FTC/TAF maintains renal function and bone mineral density to a greater extent than FTC/TDF, FTC/TAF may be a safer option for patients experiencing renal and/or bone dysfunction, for those at risk of renal and bone complications, and for those who develop FTC/TDF-related adverse events.

show abstract

“…This regime includes the pre-exposure prophylaxis (PrEP) for those HIV-naïve people-who like to engage in situational, risky sexual engagements but want to be protected-and the post-exposure prophylaxis (PEP). However, there have been problems in the implementation and use of PrEP [18]; once infected with, HIV infection remains a chronic infection, ART just provides the reduction of the viral load. Such prospects can lead to people at risk of being inconsiderate during sex, i.e., not complying with both the correct messages of the prevention campaigns and adherence to ART.…”

Section: Hiv Prevention Strategies In Europementioning

confidence: 99%

The consequences of failed HIV prevention strategies: The ongoing challenges for societies

Dennin¹,

Sinn²

2021

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

The spread of HIV in Europe is still ongoing. The established HIV prevention strategies base on structured goals to promote a behavior preventing HIV transmission, complemented by the provision of antiretroviral treatment. If followed by those people concerned, these multifactorial prevention strategies should encourage individual behavior that avoids HIV transmission in various ways, supplemented by medical help for people who are already HIV-infected. Both national and international institutions have pointed to those who present late after being infected with HIV, the undiagnosed late presenters – who unknowingly may contribute to the spread of HIV. There are already initiatives for adjustments to the prevention strategies. In this context, reference is made to the burdens on societies. In addition to the established prevention strategies, we propose the introduction of contact tracing. This measure could help reach and support people of the officially defined key populations to obey the prevention measures. This array might have a synergetic effect to contain the spread of HIV, thereby reducing the burden for societies. A juridical analysis clarifies the handling of the term discrimination. Discrimination begins where a person is penalized because they are infected or ill. However, anyone who intentionally or negligently transmits HIV to unknowing people damages a person's health and this person is therefore also held criminally responsible in all legal systems. The so-called anti-discrimination concepts in the field of criminal law must not lose sight of this distinction.

show abstract

Reviewing PrEP’s Effect on STI Incidence Among Men Who Have sex with Men—Balancing Increased STI Screening and Potential Behavioral Sexual Risk Compensation

Cited by 23 publications

References 36 publications

Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis

Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada

The consequences of failed HIV prevention strategies: The ongoing challenges for societies

Contact Info

Product

Resources

About